Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2018 Jul;104(14):1195-1199.
doi: 10.1136/heartjnl-2017-312143. Epub 2018 Feb 7.

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension

Nika Skoro-Sajer  1 , Christian Gerges  1 , Olga Hajnalka Balint  2 , Dora Kohalmi  2 , Monika Kaldararova  3 , Iveta Simkova  3 , Johannes Jakowitsch  1 , Harald Gabriel  1 , Helmut Baumgartner  4 , Mario Gerges  1 , Roela Sadushi-Kolici  1 , David S Celermajer  5 , Irene Marthe Lang  1
Affiliations
Observational Study

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension

Nika Skoro-Sajer et al. Heart. 2018 Jul.

Abstract

Objective: To assess the efficacy and safety of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after 12 months of treatment.

Methods: Consecutive adult patients with CHD-PAH received subcutaneous treprostinil to maximum tolerated doses in an observational study.

Results: Advanced CHD-PAH patients with WHO class III or IV disease (n=32, age 40±10 years, 20 females) received treprostinil for suboptimal response to bosentan (n=12), WHO functional class IV disease (FC, n=7) or prior to bosentan approval (n=13). In the multivariate mixed model, mean increase in 6 min walk distance (6-MWD) from baseline to 12 months was 114 m (76; 152) (P<0.001). WHO FC improved significantly (P=0.001) and B-type brain natriuretic peptide decreased from 1259 (375; 2368) pg/mL to 380 (144; 1468) pg/mL (P=0.02). In those 14 patients who had haemodynamic data before and after initiation of treprostinil, pulmonary vascular resistance decreased significantly (from 18.4±11.1 to 12.6±7.9 Wood units, P=0.003). The most common adverse events were infusion-site erythema and pain. One patient stopped treatment because of intolerable infusion-site pain after 8 months of treatment. No other major treatment-related complications were observed. Five patients died during early follow-up, having experienced a decrease in their 6-MWD prior.

Conclusions: Subcutaneous treprostinil therapy is generally safe and effective for at least 12 months and may be used in CHD-related PAH class III and IV.

Keywords: secondary pulmonary hypertension.

PubMed Disclaimer

Conflict of interest statement

Competing interests: NS-S reports personal fees from GlaxoSmithKline, grants and personal fees from AOPOrphan Pharmaceuticals, grants and personal fees from Actelion, personal fees from Bayer AG, personal fees from Pfizer, personal fees from United Therapeutics, outside the submitted work.

Figures

Figure 1
Figure 1
Effect of treprostinil treatment on 6 minute walking distance (6-MWD) at 6 and 12 months of treatment.
Figure 2
Figure 2
The change of WHO functional class (FC) at 6 and 12 months of treatment with subcutaneous treprostinil.
Figure 3
Figure 3
Effect of treprostinil treatment on B-type brain natriuretic peptide (BNP) values at 6 and 12 months of treatment.
See this image and copyright information in PMC

References

    1. van der Velde ET, Vander VE, Vriend JW, et al. . CONCOR, an initiative towards a national registry and DNA-bank of patients with congenital heart disease in the Netherlands: rationale, design, and first results. Eur J Epidemiol 2005;20:549–57. 10.1007/s10654-005-4264-9 - DOI - PubMed
    1. Galiè N, Humbert M, Vachiery JL, et al. . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67–119. 10.1093/eurheartj/ehv317 - DOI - PubMed
    1. Hascoet S, Fournier E, Jaïs X, et al. . Outcome of adults with Eisenmenger syndrome treated with drugs specific to pulmonary arterial hypertension: a french multicentre study. Arch Cardiovasc Dis 2017;110:303–16. 10.1016/j.acvd.2017.01.006 - DOI - PubMed
    1. Galiè N, Beghetti M, Gatzoulis MA, et al. . Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48–54. 10.1161/CIRCULATIONAHA.106.630715 - DOI - PubMed
    1. Pulido T, Adzerikho I, Channick RN, et al. . Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013;369:809–18. 10.1056/NEJMoa1213917 - DOI - PubMed

Publication types